Paravasthu Mukund
SEC CIK 2039078 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | COO | 116.1K | — | $849.6K | 14 | 2024-11-01 | 2026-03-04 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-05 | 2026-03-03 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | A - Grant | $0.00 | +45.1K | 121.5K | +59% | $0 |
| DM | 2026-03-05 | 2026-03-04+ | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $13.72 | -48.6K | 116.1K | -30% | -$667.1K |
| M | 2026-03-03 | 2026-02-27+ | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $13.62 | -1,963 | 76.3K | -3% | -$26.7K |
| 2026-01-12 | 2026-01-11 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | F - Tax | $14.35 | -2,133 | 78.3K | -3% | -$30.6K | |
| M | 2025-11-04 | 2025-11-01+ | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | F - Tax | $12.26 | -3,117 | 80.4K | -4% | -$38.2K |
| 2025-05-05 | 2025-05-03 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $17.91 | -592 | 83.6K | -0.7% | -$10.6K | |
| D | 2025-03-06 | 2025-03-04 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | A - Grant | $18.19 | +55.0K | 84.1K | +188% | +$1000.0K |
| 2025-03-04 | 2025-03-03 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $18.54 | -250 | 29.2K | -0.8% | -$4,635 | |
| M | 2025-03-03 | 2025-02-27+ | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $19.70 | -2,014 | 30.1K | -6% | -$39.7K |
| MA | 2025-03-03 | 2025-02-27+ | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $19.70 | -2,014 | 29.8K | -6% | -$39.7K |
| 2025-01-15 | 2025-01-11 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $26.81 | -2,160 | 31.4K | -6% | -$57.9K | |
| D | 2024-11-06 | 2024-11-04 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | A - Grant | $0.00 | +30.1K | 33.6K | +871% | $0 |
| D | 2024-11-06 | 2024-11-02 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $16.69 | -44 | 3,459 | -1% | -$734.36 |
| 2024-11-04 | 2024-11-01 | NVCR | NovoCure Ltd | Paravasthu Mukund | COO | S - Sale | $15.88 | -160 | 3,503 | -4% | -$2,541 |
Purchase Sale Sale after option exercise All abbreviations